XVIVO Perfusion has been approved for listing on Nasdaq Stockholm and publishes prospectus

Nasdaq Stockholm’s listing committee has approved XVIVO Perfusion AB (“XVIVO Perfusion”) for listing on the main market subject to customary conditions.

The first day of trading in XVIVO Perfusion’s shares on Nasdaq Stockholm is planned to be on Monday, 28 November 2016. Due to the listing on the main market, XVIVO Perfusion will be delisted from Nasdaq First North Premier. The last day of trading on Nasdaq First North Premier is planned to be on Friday, 25 November 2016.

XVIVO Perfusion’s shares will be traded under the same ticker symbol as before, i.e. “XVIVO”. The share will also remain the same ISIN code as used before, i.e. SE0004840718. No new shares are issued in connection with the listing and shareholders in XVIVO Perfusion do not need to take any action in connection hereto.

For further information, please refer to the prospectus (in Swedish) prepared in connection with the listing on the main market which has been approved by the Swedish Financial Supervisory Authority. The prospectus is available, inter alia, on XVIVO Perfusion’s website www.xvivoperfusion.com/corporate.

Gernandt & Danielsson is acting as legal advisor in connection with the listing.

November 21, 2016
Gothenburg
Magnus Nilsson, CEO
XVIVO Perfusion AB (publ)

For further information please contact:

Christoffer Rosenblad, CFO, +1 720 616 2101, christoffer.rosenblad@xvivoperfusion.com
Magnus Nilsson, CEO, +46 31 788 2150, magnus.nilsson@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com

The information in this press release was submitted for publication, through the agency of the contact person set out above, at 5:00 p.m. CET on November 21, 2016.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.